Delivery of Immunoprophylactics in Transgenic Plants
- 23 Downloads
The search for economic alternatives for the production of recombinant immunoprophylactics has resulted in the concept of generating them in plants at relatively low cost. Two basic strategies are employed: the expression of recombinant antigens or antibodies in transgenic plants, or the presentation of small antigen epitopes on the surface of genetically modified plant viruses. Both approaches have resulted in the production of biologically active immunoprophylactics that have been shown in animal studies to protect from the development of disease symptoms. An especially interesting feature of producing vaccines in edible plant parts is the potential to use the transgenic plant as a vehicle for oral delivery. Substantial progress has been made over the past few years, and the first clinical trials have demonstrated the potential of this new technology. Future challenges are to express the immunoprophylactics at controlled, high concentrations in plants that could be grown locally where they are needed, and to develop easy and standardised administration procedures.
KeywordsTransgenic Plant Tobacco Mosaic Virus Transgenic Potato Cowpea Mosaic Virus Mink Enteritis Virus
Financial support from Fundação de Amparo à Pesquisa do Estado de Rio de Janeiro (FAPERJ) and from Fundação Estadual do Norte Fluminense (FENORTE) is gratefully acknowledged.
- 1.Fox JL. WHO and UNICEF find vaccines too costly. Nat Biotechnol 1996; 14: 1532Google Scholar
- 7.Richter L, Kipp PB. Transgenic plants as edible vaccines. In: Hammons J, McGarvey P, Yusibov V, editors. Plant biotechnology: new products and applications. Berlin: Springer-Verlag, 1999: 159–76. (Curr Top Microbiol Immunol; 240)Google Scholar
- 19.Russell DA. Feasibility of antibody production in plants for human therapeutic use. In: Hammons J, McGarvey P, Yusibov V, editors. Plant biotechnology: new products and applications. B rlin: Springer-Verlag, 1999: 119–38. (Curr Top Microbiol Immunol; 240)Google Scholar
- 24.Arakawa T, Chong DKX, Yu J, et al. Suppression of autoimmune diabetes by a plant-delivered cholera toxin B subunit-human glutamate decarboxylase fusion protein. Transgenics 1999; 3: 51–60Google Scholar
- 30.Wigdorovitz A, Carrillo C, Santos MJD, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999; 255: 347–53PubMedCrossRefGoogle Scholar
- 54.Traavik T. Too early may be too late: ecological risks associated with the use of naked DNA as a biological tool for research, production and therapy. Research Report for the Directorate for Nature Management. Trondheim: Norway, 1999Google Scholar
- 56.Leite A, Kemper EL, Silva MJ, et al. Expression of correctly processed human growth hormone in seeds of transgenic tobacco plants. Mol Breed 1999; 9: 1–7Google Scholar